Intensified and high-dose chemotherapy with granulocyte colony- stimulating factor and autologous stem-cell transplantation support as first- line therapy in high-risk diffuse large-cell lymphoma

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 491-498

  Vitolo, U ^a   Cortellazzo, S ^a   Liberati, A M ^a   Freilone, R ^a   Falda, M ^a   Bertini, M ^a   Botto, B ^a   Cinieri, S ^a   Levis, A ^a   Locatelli, F ^a   Lovisone, E ^a   Marmont, F ^a   Pizzuti, M ^a   Rossi, A ^a   Viero, P ^a   Barbui, T ^a   Grignani, F ^a   Resegotti, L ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HEADACHE; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INTRATHECAL DRUG ADMINISTRATION; LARGE CELL LYMPHOMA; LEUKAPHERESIS; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 17144442081     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.491     Document Type: Article

References (38)

1. Coltman AC Jr, Dahlberg S, Jones ES, et al.: CHOP is curative in thirty per cent of patients with large cell lymphoma: A twelve year Southwest Oncology Group follow-up, in Skarin A (ed): Update on Treatment for Diffuse Large Cell Lymphoma. New York, NY, Park Row, 1986, pp 71-77
2. Shipp MA, Yeap BY, Harrington DP, et al.: The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 8:84-93, 1990
3. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of advanced diffuse large cell lymphoma. Ann Intern Med 102:596-602, 1985
4. Coiffier B, Gisselbrecht C, Herbrecht R, et al.: LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989
5. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
6. Cooper IA, Wolff MM, Tobertson T, et al.: Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 12:769-778, 1994
7. Velasquez WS, Jagannath S, Tucker SL, et al.: Risk classification as the basis for clinical staging of diffuse large cell lymphoma derived from 10-year survival data. Blood 74:551-557, 1989
8. Coiffier B, Lepage E: Prognosis of aggressive lymphomas: A study of five prognostic models with patients included in the LNH-84 regimen. Blood 74:558-564, 1989
9. Coiffier B, Gisselbrecht C, Vose JM, et al.: Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 9:211-217, 1991
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's Lymphoma. N Engl J Med 329:987-994, 1993
11. Philip T, Armitage JO, Spitzer G, et al.: High dose therapy and autologous bone marrow transplantation after failure of conventional therapy in adults with intermediate grade and high grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
12. Vose JM, Armitage JO, Bierman PJ, et al.: Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. Am J Med 87:285-288, 1989
13. Armitage JO, Vose JM, Bierman PJ, et al.: Salvage therapy for patients with non-Hodgkin's lymphoma. Monogr Natl Cancer Inst 10:39-43, 1990
14. Gribben JG, Goldstone AH, Linch DC, et al.: Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still sensitive to conventional dose therapy. J Clin Oncol 7:1621-1629, 1989
15. Freedman AS, Takvorian T, Anderson KC, et al.: Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 8:784-791, 1990
16. Gulati SC, Shank B, Black P, et al.: Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 6:1303-1313, 1988
17. Nademanee A, Schmidt GM, O'Donnel MR: High-dose chemotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study. Blood 80:1130-1134, 1992
18. Freedman AS, Takvorian T, Neuberg D, et al.: Autologous bone marrow transplantation in poor prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study. J Clin Oncol 11:931-936, 1993
19. Vitolo U, Bertini M, Brusamolino E, et al.: MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study. J Clin Oncol 10:219-227, 1992
20. The Non-Hodgkin's Lymphoma Classification Project: National Cancer Institue-sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
21. Jagannath S, Velasquez WS, Tucker SL, et al.: Tumor burden assessment and its implication for a poor prognostic model in advanced diffuse large cell lymphoma. J Clin Oncol 4:859-865, 1986
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete information. J Am Stat Assoc 53:547-481, 1958
23. Yan Y, Chan C, Weisenburger DD, et al.: Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol 13:1336-1342, 1995
24. Gianni AM, Bregni M, Siena S, et al.: Five-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs MACOP-B therapy for diffuse large-cell lymphomas. Proc Am Soc Clin Oncol 13:373, 1994 (abstr)
25. Haioun C, Lepage E, Gisselbrecht C, et al.: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma in first complete remission. A study of 464 patients. J Clin Oncol 12:2542-2550, 1994
26. Vitolo U, Bertini M, Tarella C, et al.: MACOP-B treatment for advanced stage diffuse large cell lymphoma. A multicenter Italian study. Eur J Cancer Clin Oncol 25:1441-1449, 1989
27. Haq R, Sawka CA, Franssen E, et al.: Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: A literature review. J Clin Oncol 12:1074-1084, 1994
28. Gherlinzoni F, Martelli M, Mazza P, et al.: Autologous bone marrow transplantation versus DHAP in aggressive non-Hodgkin's lymphomas partially responding to first-line chemotherapy. Blood 84:234a, 1994 (suppl 1, abstr)
29. Verdonck LF, Van Putten WLJ, Hagenbeek A, et al.: Comparison of CHOP chemotherapy with autologous bone marrow transplantationin for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051, 1995
30. Armitage JO: Bone marrow transplantation in the treatment of patients with lymphoma. Blood 73:1749-1758, 1989
31. Gianni AM, Siena S, Bregni M, et al.: Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 2:580-585, 1989
32. Sheridan WP, Begley CG, Juttner CA, et al.: Effect of peripheral blood progenitor cells mobilised by G-CSF (filgrastim) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992
33. To LB, Roberts MM, Haylock DN, et al.: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9:277-282, 1992
34. Pettengel R, Morgenstern GR, Woll PJ, et al.: Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 82:3770-3777, 1993
35. Miller JS, Diane CA, Craig EL, et al.: Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 83:3780-3786, 1994
36. Darrington DL, Vose JM, Anderson JR, et al.: Incidence and charcterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534, 1994
37. Stone RM, Neuberg D, Soiffer R, et al.: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535-2542, 1994
38. Shipp MA, Shulman LN, Kaplan WD, et al.: Intensified induction therapy for patients with "high-risk" aggressive NHL: High dose CHOP. Blood 82:332a, 1993 (suppl 1, abstr)